

Global Opioid-Induced Constipation Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G7071380EF1EN.html>

Date: November 2017

Pages: 189

Price: US\$ 4,400.00 (Single User License)

ID: G7071380EF1EN

Abstracts

Opioid-Induced Constipation Treatment Market Reports

Global Opioid-Induced Constipation Treatment Market are the drugs used for its pain relieving properties in non-cancer and chronic pain. The adverse effects associated with the opioids are decreasing gastrointestinal tract's motility, making patient's strain, and making of solid discharges. Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard stools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite.

The opioid-induced constipation treatment market growing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global opioid-induced constipation treatment market. Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the opioid-induced constipation treatment market over the forecast period. However, lack of awareness regarding opioid-induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the

opioid-induced constipation treatment market.

The opioid-induced constipation treatment market is segmented on the basis of drug type, formulation type, route of administration, and distribution channel

Based on drug type, opioid-induced constipation treatment market has been segmented into the following

Peripherally restricted μ -opioid receptor antagonists

Non-selective opioid antagonists

μ -opioid receptor antagonists

Locally acting chloride channel activators

Based on formulation type, opioid-induced constipation treatment market has been segmented into the following

Solids

Semi-solids

Liquids

Based on route of administration, opioid-induced constipation treatment market has been segmented into the following

Oral

Parenteral (Subcutaneous Injection)

Based on distribution channel, opioid-induced constipation treatment market has been segmented into the following

Drugstore

Retail pharmacies

Hospital pharmacies

The Global Opioid-Induced Constipation Treatment Market is in the growing stage, several players are actively engaged in the development of the opioid-induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation treatment market products to drive the market growth. For instance, in March 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors fuelling the growth of the opioid-induced constipation treatment market. For instance, Linaclotide was approved by the FDA in August 2012 and by the European Medicines Agency for the treatment in adults with constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Geographically, Global Opioid-Induced Constipation Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in the opioid-induced constipation treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients, According to the American Society of Interventional Pain Physician, in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.

Some of the players in the opioid-induced constipation treatment market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG

(U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc. (U.S.) and Cosmo Pharmaceuticals N.V. (Ireland) to name a few.

In March 2017, FDA approved Symphonic (Naldemedine) for the treatment of Opioid-Induced Constipation, which was manufactured by Purdue Pharma LP and Shionogi

In March 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (Naloxegol) in the European Union (EU)

Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings, and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET INTRODUCTION

2.1. Global Opioid-Induced Constipation Treatment Market – Taxonomy

2.2. Global Opioid-Induced Constipation Treatment Market –Definitions

2.2.1. Type of vaccine

2.2.2. End User

3. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Opioid-Induced Constipation Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Opioid-Induced Constipation Treatment Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Opioid-Induced Constipation Treatment Market – Product Innovations

4. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Peripherally restricted μ -opioid receptor antagonists

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

- 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 5.1.3. Market Opportunity Analysis
- 5.2. Non-selective opioid antagonists
 - 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.2.3. Market Opportunity Analysis
- 5.3. μ -opioid receptor antagonists
 - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.3.3. Market Opportunity Analysis

6. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY FORMULATION TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Solids
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.1.3. Market Opportunity Analysis
- 6.2. Semi-Solids
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.2.3. Market Opportunity Analysis
- 6.3. Liquids
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.3.3. Market Opportunity Analysis

7. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

- 7.1. Oral
 - 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.1.3. Market Opportunity Analysis
- 7.2. Parenteral
 - 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.2.3. Market Opportunity Analysis

8. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Drug Stores

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.1.3. Market Opportunity Analysis

8.2. Retail Pharmacies

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.2.3. Market Opportunity Analysis

8.3. Hospital Pharmacies

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.3.3. Market Opportunity Analysis

9. GLOBAL OPIOID-INDUCED CONSTIPATION TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America

- 9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.1.3. Market Opportunity Analysis

9.2. Europe

- 9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

- 9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.3.3. Market Opportunity Analysis

9.4. Latin America

- 9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.4.3. Market Opportunity Analysis

9.5. Middle East and Africa

- 9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.5.3. Market Opportunity Analysis

9.6. Global Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2017 – 2023

10. NORTH AMERICA OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Peripherally restricted μ -opioid receptor antagonists

10.1.1.2. Non-selective opioid antagonists

10.1.1.3. κ -opioid receptor antagonists

10.1.1.4. Locally acting chloride channel activators

10.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Solids

10.1.2.2. Semi-Solids

10.1.2.3. Liquids

10.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Oral

10.1.3.2. Parenteral

10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Drugstore

10.1.4.2. Retail pharmacies

10.1.4.3. Hospital pharmacies

10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.1.5.1. U.S.

10.1.5.2. Canada

10.1.6. North America Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023

10.1.7. North America Opioid-Induced Constipation Treatment Market Dynamics – Trends

11. EUROPE OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Peripherally restricted μ -opioid receptor antagonists

11.1.1.2. Non-selective opioid antagonists

11.1.1.3. κ -opioid receptor antagonists

11.1.1.4. Locally acting chloride channel activators

11.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Solids

11.1.2.2. Semi-Solids

11.1.2.3. Liquids

11.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Oral

11.1.3.2. Parenteral

11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.4.1. Drugstore

11.1.4.2. Retail pharmacies

11.1.4.3. Hospital pharmacies

11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.5.1. Germany

11.1.5.2. UK

11.1.5.3. France

11.1.5.4. Spain

11.1.5.5. Italy

11.1.5.6. Russia

11.1.5.7. Poland

11.1.5.8. Rest of Europe

11.1.6. Europe Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023

11.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics – Trends

12. ASIA-PACIFIC OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Peripherally restricted μ -opioid receptor antagonists

12.1.1.2. Non-selective opioid antagonists

12.1.1.3. κ -opioid receptor antagonists

12.1.1.4. Locally acting chloride channel activators

12.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Solids

12.1.2.2. Semi-Solids

12.1.2.3. Liquids

12.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Oral

12.1.3.2. Parenteral

12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Drugstore

12.1.4.2. Retail pharmacies

12.1.4.3. Hospital pharmacies

12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

12.1.5.1. Japan

12.1.5.2. China

12.1.5.3. India

12.1.5.4. ASEAN

12.1.5.5. Australia & New Zealand

12.1.5.6. Rest of Asia-Pacific

12.1.6. Asia-Pacific Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023

12.1.7. Europe Opioid-Induced Constipation Treatment Market Dynamics – Trends

13. LATIN AMERICA OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Peripherally restricted μ -opioid receptor antagonists

- 13.1.1.2. Non-selective opioid antagonists
- 13.1.1.3. μ -opioid receptor antagonists
- 13.1.1.4. Locally acting chloride channel activators
- 13.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.2.1. Solids
 - 13.1.2.2. Semi-Solids
 - 13.1.2.3. Liquids
- 13.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.3.1. Oral
 - 13.1.3.2. Parenteral
- 13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.4.1. Drugstore
 - 13.1.4.2. Retail pharmacies
 - 13.1.4.3. Hospital pharmacies
- 13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.5.1. Brazil
 - 13.1.5.2. Mexico
 - 13.1.5.3. Argentina
 - 13.1.5.4. Venezuela
 - 13.1.5.5. Rest of Latin America
- 13.1.6. Latin America Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023
- 13.1.7. Latin America Opioid-Induced Constipation Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA OPIOID-INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 14.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 14.1.1.1. Peripherally restricted μ -opioid receptor antagonists
 - 14.1.1.2. Non-selective opioid antagonists
 - 14.1.1.3. μ -opioid receptor antagonists
 - 14.1.1.4. Locally acting chloride channel activators

14.1.2. Formulation Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.2.1. Solids

14.1.2.2. Semi-Solids

14.1.2.3. Liquids

14.1.3. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.3.1. Oral

14.1.3.2. Parenteral

14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.4.1. Drugstore

14.1.4.2. Retail pharmacies

14.1.4.3. Hospital pharmacies

14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.5.1. Gulf Cooperation Council (GCC) Countries

14.1.5.2. Israel

14.1.5.3. South Africa

14.1.5.4. Rest of MEA

14.1.6. MEA Opioid-Induced Constipation Treatment Market - Opportunity Analysis Index, By Drug Analysis, Formulation Type, Route of Administration, Distribution Channel, and Country, 2017 – 2023

14.1.7. MEA Opioid-Induced Constipation Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. GlaxoSmithKline plc (U.K.)

15.2.2. AstraZeneca U.K)

15.2.3. Pfizer Inc. (U.S.)

15.2.4. SLA Pharma AG (U.K.)

15.2.5. AIKO Biotechnology, Inc. (U.S.)

15.2.6. Cubist Pharmaceuticals (Merck & Co. Inc.,) (U.S.)

15.2.7. Takeda Pharmaceutical Company Limited (Japan)

15.2.8. Boehringer Ingelheim GmbH (Germany)

15.2.9. Bayer AG (Germany)

- 15.2.10. Valeant (Canada)
- 15.2.11. Abbott Laboratories (U.S.)
- 15.2.12. Purdue Pharma LP (U.S.)
- 15.2.13. Shionogi Inc. (U.S.)
- 15.2.14. Cosmo Pharmaceuticals N.V. (Ireland)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Opioid-Induced Constipation Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G7071380EF1EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7071380EF1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

